Mark Kester - Publications

Affiliations: 
Pennsylvania State University, State College, PA, United States 
Area:
Pharmacology, Neuroscience Biology

145 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2024 Ohya Y, Ogiso Y, Matsuda M, Sakae H, Nishida K, Miki Y, Fox TE, Kester M, Sakamoto W, Nabe T, Kitatani K. Pronecroptotic Therapy Using Ceramide Nanoliposomes Is Effective for Triple-Negative Breast Cancer Cells. Cells. 13. PMID 38474369 DOI: 10.3390/cells13050405  0.6
2024 Paudel BB, Tan SF, Fox TE, Ung J, Golla U, Shaw JJP, Dunton W, Lee IS, Fares W, Patel S, Sharma A, Viny AD, Barth BM, Tallman MS, Cabot MC, ... ... Kester M, et al. Acute myeloid leukemia stratifies as two clinically relevant sphingolipidomic subtypes. Blood Advances. PMID 38170742 DOI: 10.1182/bloodadvances.2023010535  0.477
2023 Feng TY, Melchor SJ, Zhao XY, Ghumman H, Kester M, Fox TE, Ewald SE. Tricarboxylic acid (TCA) cycle, sphingolipid, and phosphatidylcholine metabolism are dysregulated in infection-induced cachexia. Heliyon. 9: e17411. PMID 37456044 DOI: 10.1016/j.heliyon.2023.e17411  0.521
2023 Thim EA, Fox T, Deering T, Vass LR, Sheybani ND, Kester M, Price RJ. Solid tumor treatment via augmentation of bioactive C6 ceramide levels with thermally ablative focused ultrasound. Drug Delivery and Translational Research. PMID 37335416 DOI: 10.1007/s13346-023-01377-w  0.55
2023 Paudel BB, Tan SF, Fox TE, Ung J, Shaw J, Dunton W, Lee I, Sharma A, Viny AD, Barth BM, Tallman MS, Cabot M, Garrett-Bakelman FE, Levine RL, Kester M, et al. Acute myeloid leukemia stratifies as two clinically relevant sphingolipidomic subtypes. Biorxiv : the Preprint Server For Biology. PMID 37131653 DOI: 10.1101/2023.04.13.536805  0.502
2023 Thim EA, Fox T, Deering T, Vass LR, Sheybani ND, Kester M, Price RJ. Solid Tumor Treatment via Augmentation of Bioactive C6 Ceramide Levels with Thermally Ablative Focused Ultrasound. Biorxiv : the Preprint Server For Biology. PMID 36993445 DOI: 10.1101/2023.03.23.532394  0.549
2023 Fisher-Wellman KH, Kassai M, Hagen JT, Neufer PD, Kester M, Loughran TP, Chalfant CE, Feith DJ, Tan SF, Fox TE, Ung J, Fabrias G, Abad JL, Sharma A, Golla U, et al. Simultaneous Inhibition of Ceramide Hydrolysis and Glycosylation Synergizes to Corrupt Mitochondrial Respiration and Signal Caspase Driven Cell Death in Drug-Resistant Acute Myeloid Leukemia. Cancers. 15. PMID 36980769 DOI: 10.3390/cancers15061883  0.569
2023 Sakae H, Ogiso Y, Matsuda M, Shimora H, Deering T, Fox TE, Kester M, Nabe T, Kitatani K. Ceramide Nanoliposomes as Potential Therapeutic Reagents for Asthma. Cells. 12. PMID 36831258 DOI: 10.3390/cells12040591  0.546
2022 Salotto KE, Olson WC, Pollack KE, Illendula A, Michel E, Henriques S, Fox T, Walker S, Dunlap-Brown M, Slingluff CL, Kester M, Snyder HW. A nano-enhanced vaccine for metastatic melanoma immunotherapy. Cancer Drug Resistance (Alhambra, Calif.). 5: 829-845. PMID 36176766 DOI: 10.20517/cdr.2021.132  0.534
2022 Khokhlatchev AV, Sharma A, Deering TG, Shaw JJP, Costa-Pinheiro P, Golla U, Annageldiyev C, Cabot MC, Conaway MR, Tan SF, Ung J, Feith DJ, Loughran TP, Claxton DF, Fox TE, ... Kester M, et al. Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 36: e22514. PMID 36106439 DOI: 10.1096/fj.202200765R  0.615
2022 LeBlanc FR, Hasanali ZS, Stuart A, Shimko S, Sharma K, Leshchenko VV, Parekh S, Fu H, Zhang Y, Martin MM, Kester M, Fox T, Liao J, Loughran TP, Evans J, et al. Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma. Oncotarget. 13: 986-1002. PMID 36093297 DOI: 10.18632/oncotarget.28258  0.542
2022 Ung J, Tan SF, Fox TE, Shaw JJP, Vass LR, Costa-Pinheiro P, Garrett-Bakelman FE, Keng MK, Sharma A, Claxton DF, Levine RL, Tallman MS, Cabot MC, Kester M, Feith DJ, et al. Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia. Blood Reviews. 100950. PMID 35487785 DOI: 10.1016/j.blre.2022.100950  0.558
2022 DiPasquale M, Deering TG, Desai D, Sharma AK, Amin S, Fox TE, Kester M, Katsaras J, Marquardt D, Heberle FA. Influence of ceramide on lipid domain stability studied with small-angle neutron scattering: The role of acyl chain length and unsaturation. Chemistry and Physics of Lipids. 105205. PMID 35483419 DOI: 10.1016/j.chemphyslip.2022.105205  0.53
2022 Qi X, Wu F, Kim SH, Kaifi JT, Kimchi ET, Snyder H, Illendula A, Fox T, Kester M, Staveley-O'Carroll KF, Li G. Nanoliposome C6-Ceramide in combination with anti-CTLA4 antibody improves anti-tumor immunity in hepatocellular cancer. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 36: e22250. PMID 35294071 DOI: 10.1096/fj.202101707R  0.532
2022 Fisher-Wellman KH, Hagen JT, Kassai M, Kao LP, Nelson MAM, McLaughlin KL, Coalson HS, Fox TE, Tan SF, Feith DJ, Kester M, Loughran TP, Claxton DF, Cabot MC. Alterations in sphingolipid composition and mitochondrial bioenergetics represent synergistic therapeutic vulnerabilities linked to multidrug resistance in leukemia. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 36: e22094. PMID 34888943 DOI: 10.1096/fj.202101194RRR  0.559
2021 Golla U, Ehudin MA, Annageldiyev C, Zeng Z, Bastihalli Tukaramrao D, Tarren A, Date AA, Elcheva I, Berg A, Amin S, Loughran TP, Kester M, Desai D, Dovat S, Claxton D, et al. DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia. Cancers. 13. PMID 34638385 DOI: 10.3390/cancers13194889  0.311
2020 Costa-Pinheiro P, Heher A, Raymond MH, Jividen K, Shaw JJ, Paschal BM, Walker SJ, Fox TE, Kester M. Role of SPTSSB-Regulated de Novo Sphingolipid Synthesis in Prostate Cancer Depends on Androgen Receptor Signaling. Iscience. 23: 101855. PMID 33313495 DOI: 10.1016/j.isci.2020.101855  0.559
2020 Shaw JJ, Boyer TL, Venner E, Beck PJ, Slamowitz T, Caste T, Hickman A, Raymond MH, Costa-Pinheiro P, Jameson MJ, Fox TE, Kester M. Inhibition of Lysosomal Function Mitigates Protective Mitophagy and Augments Ceramide Nanoliposome-Induced Cell Death in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics. PMID 33087509 DOI: 10.1158/1535-7163.MCT-20-0182  0.571
2020 Patterson L, Allen J, Posey I, Shaw JJP, Costa-Pinheiro P, Walker SJ, Gademsey A, Wu X, Wu S, Zachos NC, Fox TE, Sears CL, Kester M. Glucosylceramide production maintains colon integrity in response to Bacteroides fragilis toxin-induced colon epithelial cell signaling. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 33047400 DOI: 10.1096/fj.202001669R  0.55
2020 Keppley LJW, Walker SJ, Gademsey AN, Smith JP, Keller SR, Kester M, Fox TE. Nervonic acid limits weight gain in a mouse model of diet-induced obesity. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 32959931 DOI: 10.1096/Fj.202000525R  0.531
2020 Zanieri F, Levi A, Montefusco D, Longato L, De Chiara F, Frenguelli L, Omenetti S, Andreola F, Luong TV, Massey V, Caballeria J, Fondevila C, Shanmugavelandy SS, Fox T, Mazza G, ... ... Kester M, et al. Exogenous Liposomal Ceramide-C6 Ameliorates Lipidomic Profile, Energy Homeostasis, and Anti-Oxidant Systems in NASH. Cells. 9. PMID 32429478 DOI: 10.3390/Cells9051237  0.624
2020 Drews K, Calgi MP, Harrison WC, Drews CM, Costa-Pinheiro P, Shaw JJP, Jobe KA, Han JD, Fox TE, White JM, Kester M. Glucosylceramide synthase maintains influenza virus entry and infection. Plos One. 15: e0228735. PMID 32032363 DOI: 10.1371/Journal.Pone.0228735  0.544
2020 Costa-Pinheiro P, Heher A, Raymond M, Jividen K, Fox T, Kester M. Abstract 2079: Ceramide nanoliposomes a novel therapeutic option for androgen receptor negative prostate cancer Epidemiology. DOI: 10.1158/1538-7445.Am2020-2079  0.547
2019 Pearson JM, Tan SF, Sharma A, Annageldiyev C, Fox TE, Abad JL, Fabrias G, Desai D, Amin S, Wang HG, Cabot MC, Claxton DF, Kester M, Feith DJ, Loughran TP. Ceramide analog SACLAC modulates sphingolipid levels and Mcl-1 splicing to induce apoptosis in acute myeloid leukemia. Molecular Cancer Research : McR. PMID 31744877 DOI: 10.1158/1541-7786.Mcr-19-0619  0.641
2019 Barth BM, Wang W, Toran PT, Fox TE, Annageldiyev C, Ondrasik RM, Keasey NR, Brown TJ, Devine VG, Sullivan EC, Cote AL, Papakotsi V, Tan SF, Shanmugavelandy SS, Deering TG, ... ... Kester M, et al. Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia. Blood Advances. 3: 2598-2603. PMID 31488436 DOI: 10.1182/Bloodadvances.2018021295  0.583
2019 Kao LP, Morad SAF, Davis TS, MacDougall MR, Kassai M, Abdelmageed N, Fox TE, Kester M, Loughran TP, Abad JL, Fabrias G, Tan SF, Feith DJ, Claxton DF, Spiegel S, et al. Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells. Journal of Lipid Research. PMID 31363040 DOI: 10.1194/Jlr.Ra119000251  0.653
2019 Moore JH, Varhue WB, Su YH, Linton SS, Farmehini V, Fox TE, Matters GL, Kester M, Swami NS. Conductance-based biophysical distinction and microfluidic enrichment of nano-vesicles derived from pancreatic tumor cells of varying invasiveness. Analytical Chemistry. PMID 31333013 DOI: 10.1021/Acs.Analchem.8B05745  0.593
2019 Morad SAF, MacDougall MR, Abdelmageed N, Kao LP, Feith DJ, Tan SF, Kester M, Loughran TP, Wang HG, Cabot MC. Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen. Experimental Cell Research. PMID 31112736 DOI: 10.1016/J.Yexcr.2019.05.021  0.457
2019 Tan SF, Dunton W, Liu X, Fox TE, Morad SAF, Desai D, Doi K, Conaway MR, Amin S, Claxton DF, Wang HG, Kester M, Cabot MC, Feith DJ, Loughran TP. Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-kB-dependent P-glycoprotein upregulation. Journal of Lipid Research. PMID 30962310 DOI: 10.1194/Jlr.M091876  0.572
2019 Drews K, Calgi MP, Harrison WC, Drews CM, Costa-Pinheiro P, Shaw JJP, Jobe KA, Nelson EA, Han JD, Fox T, White JM, Kester M. Glucosylceramidase Maintains Influenza Infection By Regulating Endocytosis. Journal of Virology. PMID 30918081 DOI: 10.1128/Jvi.00017-19  0.562
2019 Lu P, White-Gilbertson S, Nganga R, Kester M, Voelkel-Johnson C. Expression of the SNAI2 transcriptional repressor is regulated by C-ceramide. Cancer Biology & Therapy. 1-9. PMID 30836822 DOI: 10.1080/15384047.2019.1579962  0.395
2018 Linton SS, Abraham T, Liao J, Clawson GA, Butler PJ, Fox T, Kester M, Matters GL. Tumor-promoting effects of pancreatic cancer cell exosomes on THP-1-derived macrophages. Plos One. 13: e0206759. PMID 30383833 DOI: 10.1371/Journal.Pone.0206759  0.592
2018 Shaw J, Costa-Pinheiro P, Patterson L, Drews K, Spiegel S, Kester M. Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era. Advances in Cancer Research. 140: 327-366. PMID 30060815 DOI: 10.1016/Bs.Acr.2018.04.016  0.383
2018 Li G, Liu D, Kimchi ET, Kaifi JT, Qi X, Manjunath Y, Liu X, Deering T, Fox T, Rockey DC, Schell TD, Kester M, Avella DM, Staveley-O'Carroll KF. Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice. Gastroenterology. PMID 29408569 DOI: 10.1053/J.Gastro.2017.10.050  0.562
2018 Annageldiyev C, Sharma A, Barth BM, Fox TE, Deering T, Devine V, Keasey NR, Stern ST, Young MM, Wang HW, Liao J, Zhu J, Viny AD, Levine RL, Loughran TP, ... Kester M, et al. Abstract 5832: Sphingolipid metabolism determines the efficacy of nanoliposomal ceramide in acute myeloid leukemia Cancer Research. 78: 5832-5832. DOI: 10.1158/1538-7445.Am2018-5832  0.436
2017 Doshi UA, Shaw J, Fox TE, Claxton DF, Loughran TP, Kester M. STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia. Signal Transduction and Targeted Therapy. 2: 17051. PMID 29263930 DOI: 10.1038/Sigtrans.2017.51  0.67
2017 Zhang X, Kitatani K, Toyoshima M, Ishibashi M, Usui T, Minato J, Egiz M, Shigeta S, Fox T, Deering T, Kester M, Yaegashi N. Ceramide nanoliposomes as a MLKL-dependent, necroptosis-inducing, chemotherapeutic reagent in ovarian cancer. Molecular Cancer Therapeutics. PMID 29079707 DOI: 10.1158/1535-7163.Mct-17-0173  0.657
2017 Shin M, Snyder HW, Donvito G, Schurman LD, Fox TE, Lichtman AH, Kester M, Hsu KL. Liposomal Delivery of Diacylglycerol Lipase-Beta Inhibitors to Macrophages Dramatically Enhances Selectivity and Efficacy in Vivo. Molecular Pharmaceutics. PMID 28901776 DOI: 10.1021/Acs.Molpharmaceut.7B00657  0.583
2017 Hengst JA, Dick TE, Sharma A, Doi K, Hegde S, Tan SF, Geffert LM, Fox TE, Sharma AK, Desai D, Amin S, Kester M, Loughran TP, Paulson RF, Claxton DF, et al. SKI-178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models. Cancer Translational Medicine. 3: 109-121. PMID 28890935 DOI: 10.4103/Ctm.Ctm_7_17  0.585
2017 Tang X, Loc WS, Dong C, Matters GL, Butler PJ, Kester M, Meyers C, Jiang Y, Adair JH. The use of nanoparticulates to treat breast cancer. Nanomedicine (London, England). PMID 28868970 DOI: 10.2217/Nnm-2017-0202  0.317
2017 Camp ER, Patterson LD, Kester M, Voelkel-Johnson C. Therapeutic Implications Of Bioactive Sphingolipids: A Focus On Colorectal Cancer. Cancer Biology & Therapy. 0. PMID 28686076 DOI: 10.1080/15384047.2017.1345396  0.334
2017 Loc WS, Linton SS, Wilczynski ZR, Matters GL, McGovern CO, Abraham T, Fox T, Gigliotti CM, Tang X, Tabakovic A, Martin JA, Clawson GA, Smith JP, Butler PJ, Kester M, et al. Effective Encapsulation and Biological Activity of Phosphorylated Chemotherapeutics in Calcium Phosphosilicate Nanoparticles for the Treatment of Pancreatic Cancer. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 28673852 DOI: 10.1016/J.Nano.2017.06.017  0.62
2017 Vijayan M, Xia C, Song YE, Ngo H, Studstill CJ, Drews K, Fox TE, Johnson MC, Hiscott J, Kester M, Alexander S, Hahm B. Sphingosine 1-Phosphate Lyase Enhances the Activation of IKKε To Promote Type I IFN-Mediated Innate Immune Responses to Influenza A Virus Infection. Journal of Immunology (Baltimore, Md. : 1950). PMID 28600291 DOI: 10.4049/Jimmunol.1601959  0.561
2017 Morad SA, Davis TS, MacDougall MR, Tan SF, Feith DJ, Desai DH, Amin SG, Kester M, Loughran TP, Cabot MC. Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer. Biochemical Pharmacology. PMID 28189725 DOI: 10.1016/J.Bcp.2017.02.002  0.464
2017 Pearson JM, Tan S, Sharma A, Fox TE, Abad JL, Fabrias G, Claxton DF, Feith DJ, Kester M, Loughran TP. Abstract 48: Acid ceramidase inhibition: A targeted therapy for acute myeloid leukemia Clinical Cancer Research. 23: 48-48. DOI: 10.1158/1557-3265.Hemmal17-48  0.391
2017 Llaneza DC, Deering TG, Sherwood SG, Cornelison JR, Kester M, Landen CN. Abstract 3083A: C6-ceramide nanoliposomes sensitize paclitaxel resistant ovarian cancer cells to chemotherapy treatment Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-3083A  0.342
2016 Tan SF, Liu X, Fox TE, Barth BM, Sharma A, Turner SD, Awwad A, Dewey A, Doi K, Spitzer B, Shah MV, Morad SA, Desai D, Amin S, Zhu J, ... ... Kester M, et al. Acid ceramidase is upregulated in AML and represents a novel therapeutic target. Oncotarget. PMID 27825124 DOI: 10.18632/Oncotarget.13079  0.641
2016 Young MM, Takahashi Y, Fox TE, Yun JK, Kester M, Wang HG. Sphingosine Kinase 1 Cooperates with Autophagy to Maintain Endocytic Membrane Trafficking. Cell Reports. 17: 1532-1545. PMID 27806293 DOI: 10.1016/J.Celrep.2016.10.019  0.573
2016 Clawson GA, Abraham T, Pan W, Tang X, Linton SS, McGovern CO, Loc WS, Smith JP, Butler PJ, Kester M, Adair JH, Matters GL. A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma. Nucleic Acid Therapeutics. PMID 27754762 DOI: 10.1089/Nat.2016.0621  0.31
2016 Morad SA, Ryan TE, Neufer PD, Zeczycki TN, Davis TS, MacDougall MR, Fox TE, Tan SF, Feith DJ, Loughran TP, Kester M, Claxton DF, Barth BM, Deering TG, Cabot MC. Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia. Journal of Lipid Research. PMID 27140664 DOI: 10.1194/Jlr.M067389  0.655
2016 Morad SA, Bridges LC, Almeida Larrea AD, Mayen AL, MacDougall MR, Davis TS, Kester M, Cabot MC. Short-chain ceramides depress integrin cell surface expression and function in colorectal cancer cells. Cancer Letters. PMID 27045476 DOI: 10.1016/J.Canlet.2016.03.049  0.437
2016 Skibinski CG, Das A, Chen KM, Liao J, Manni A, Kester M, El-Bayoumy K. A novel biologically active acid stable liposomal formulation of docosahexaenoic acid in human breast cancer cell lines. Chemico-Biological Interactions. PMID 27041074 DOI: 10.1016/J.Cbi.2016.03.035  0.398
2016 Rivera IG, Ordoñez M, Presa N, Gangoiti P, Gomez-Larrauri A, Trueba M, Fox T, Kester M, Gomez-Muñoz A. Ceramide 1-phosphate regulates cell migration and invasion of human pancreatic cancer cells. Biochemical Pharmacology. 102: 107-19. PMID 26707801 DOI: 10.1016/J.Bcp.2015.12.009  0.658
2016 Linton SS, Sherwood SG, Drews KC, Kester M. Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine. Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology. 8: 208-22. PMID 26153136 DOI: 10.1002/Wnan.1358  0.356
2016 Dick TE, Hengst JA, Geffert LM, Paulson RF, Wang H, Claxton DF, Kester M, Loughran TP, Yun JK. Abstract 323: SKI-178, a single agent co-targeting sphingosine kinase 1 and microtubule dynamics, as a therapeutic strategy for treatment of acute myeloid leukemia Cancer Research. 76: 323-323. DOI: 10.1158/1538-7445.Am2016-323  0.303
2016 Rivera IG, Ordoñez M, Presa N, Gangoiti P, Gomez-Larrauri A, Trueba M, Fox T, Kester M, Gomez-Muñoz A. Ceramide 1-phosphate regulates cell migration and invasion of human pancreatic cancer cells Biochemical Pharmacology. 102: 107-119. DOI: 10.1016/j.bcp.2015.12.009  0.579
2015 Morad SA, Davis TS, Kester M, Loughran TP, Cabot MC. Dynamics of ceramide generation and metabolism in response to fenretinide - Diversity within and among leukemia. Leukemia Research. 39: 1071-8. PMID 26220867 DOI: 10.1016/J.Leukres.2015.06.009  0.419
2015 Kester M, Bassler J, Fox TE, Carter CJ, Davidson JA, Parette MR. Preclinical development of a C6-ceramide NanoLiposome, a novel sphingolipid therapeutic. Biological Chemistry. 396: 737-47. PMID 25838296 DOI: 10.1515/Hsz-2015-0129  0.569
2015 Morad SA, Tan SF, Feith DJ, Kester M, Claxton DF, Loughran TP, Barth BM, Fox TE, Cabot MC. Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia-Impact on enzyme activity and response to cytotoxics. Biochimica Et Biophysica Acta. 1851: 919-28. PMID 25769964 DOI: 10.1016/J.Bbalip.2015.03.001  0.668
2015 Haakenson JK, Khokhlatchev AV, Choi YJ, Linton SS, Zhang P, Zaki PM, Fu C, Cooper TK, Manni A, Zhu J, Fox TE, Dong C, Kester M. Lysosomal degradation of CD44 mediates ceramide nanoliposome-induced anoikis and diminished extravasation in metastatic carcinoma cells. The Journal of Biological Chemistry. 290: 8632-43. PMID 25681441 DOI: 10.1074/Jbc.M114.609677  0.614
2015 Dick TE, Hengst JA, Fox TE, Colledge AL, Kale VP, Sung SS, Sharma A, Amin S, Loughran TP, Kester M, Wang HG, Yun JK. The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines. The Journal of Pharmacology and Experimental Therapeutics. 352: 494-508. PMID 25563902 DOI: 10.1124/Jpet.114.219659  0.65
2015 Brinton LT, Sloane HS, Kester M, Kelly KA. Formation and role of exosomes in cancer. Cellular and Molecular Life Sciences : Cmls. 72: 659-71. PMID 25336151 DOI: 10.1007/S00018-014-1764-3  0.374
2015 Doshi UA, Loughran TP, Kester M. Abstract 2613: STAT3 mediates C6-ceramide-induced cell death in chronic lymphocytic leukemia via the MEK/ERK and PKC pathway Cancer Research. 75: 2613-2613. DOI: 10.1158/1538-7445.Am2015-2613  0.484
2015 Morad SAF, Ryan TE, Barth BM, Claxton DF, Kester M, Loughran TP, Cabot MC. Abstract B17: Ceramide-antiestrogen regimen targets bioenergetic elements in acute myelogenous leukemia Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B17  0.441
2014 Barth BM, Keasey NR, Wang X, Shanmugavelandy SS, Rampal R, Hricik T, Cabot MC, Kester M, Wang HG, Shultz LD, Tallman MS, Levine RL, Loughran TP, Claxton DF. Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rγnull Mice for Preclinical Ceramide-Based Therapeutic Evaluation. Journal of Leukemia (Los Angeles, Calif.). 2. PMID 28239612 DOI: 10.4172/2329-6917.1000146  0.368
2014 Loc WS, Smith JP, Matters G, Kester M, Adair JH. Novel strategies for managing pancreatic cancer. World Journal of Gastroenterology : Wjg. 20: 14717-25. PMID 25356034 DOI: 10.3748/Wjg.V20.I40.14717  0.315
2014 Skibinski CG, Das A, Kester M, Chen K, Manni A, El-Bayoumy K. Abstract 5421: A novel biologically active acid stable liposomal formulation of docosahexaenoic acid (DHA) for breast cancer prevention Cancer Research. 74: 5421-5421. DOI: 10.1158/1538-7445.Am2014-5421  0.355
2014 McGovern C, Shanmugavelandy S, Shimko S, Linton S, Dai J, Kester M, Smith JP, Matters GL. Abstract 5404: C6-ceramide containing anionic nanoliposomes are effective chemotherapy delivery vehicles for pancreatic cancer Cancer Research. 74: 5404-5404. DOI: 10.1158/1538-7445.Am2014-5404  0.393
2013 Jiang Y, DiVittore NA, Young MM, Jia Z, Xie K, Ritty TM, Kester M, Fox TE. Altered sphingolipid metabolism in patients with metastatic pancreatic cancer. Biomolecules. 3: 435-48. PMID 24970174 DOI: 10.3390/biom3030435  0.542
2013 Ryland LK, Doshi UA, Shanmugavelandy SS, Fox TE, Aliaga C, Broeg K, Baab KT, Young M, Khan O, Haakenson JK, Jarbadan NR, Liao J, Wang HG, Feith DJ, Loughran TP, ... ... Kester M, et al. C6-ceramide nanoliposomes target the Warburg effect in chronic lymphocytic leukemia. Plos One. 8: e84648. PMID 24367685 DOI: 10.1371/Journal.Pone.0084648  0.822
2013 Hankins JL, Ward KE, Linton SS, Barth BM, Stahelin RV, Fox TE, Kester M. Ceramide 1-phosphate mediates endothelial cell invasion via the annexin a2-p11 heterotetrameric protein complex. The Journal of Biological Chemistry. 288: 19726-38. PMID 23696646 DOI: 10.1074/Jbc.M113.481622  0.785
2013 Adiseshaiah PP, Clogston JD, McLeland CB, Rodriguez J, Potter TM, Neun BW, Skoczen SL, Shanmugavelandy SS, Kester M, Stern ST, McNeil SE. Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models. Cancer Letters. 337: 254-65. PMID 23664889 DOI: 10.1016/J.Canlet.2013.04.034  0.446
2013 Hankins JL, Doshi UA, Haakenson JK, Young MM, Barth BM, Kester M. The therapeutic potential of nanoscale sphingolipid technologies. Handbook of Experimental Pharmacology. 197-210. PMID 23579457 DOI: 10.1007/978-3-7091-1368-4_11  0.77
2013 Barth BM, Shanmugavelandy SS, Kaiser JM, McGovern C, AltınoÄŸlu EÄ°, Haakenson JK, Hengst JA, Gilius EL, Knupp SA, Fox TE, Smith JP, Ritty TM, Adair JH, Kester M. PhotoImmunoNanoTherapy reveals an anticancer role for sphingosine kinase 2 and dihydrosphingosine-1-phosphate. Acs Nano. 7: 2132-44. PMID 23373542 DOI: 10.1021/Nn304862B  0.659
2013 Morad SA, Madigan JP, Levin JC, Abdelmageed N, Karimi R, Rosenberg DW, Kester M, Shanmugavelandy SS, Cabot MC. Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53. Biochemical Pharmacology. 85: 1057-65. PMID 23353700 DOI: 10.1016/J.Bcp.2013.01.015  0.436
2013 Watters RJ, Fox TE, Tan SF, Shanmugavelandy S, Choby JE, Broeg K, Liao J, Kester M, Cabot MC, Loughran TP, Liu X. Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia. Leukemia & Lymphoma. 54: 1288-96. PMID 23181473 DOI: 10.3109/10428194.2012.752485  0.658
2013 Young MM, Kester M, Wang HG. Sphingolipids: regulators of crosstalk between apoptosis and autophagy. Journal of Lipid Research. 54: 5-19. PMID 23152582 DOI: 10.1194/Jlr.R031278  0.379
2013 Kaiser JM, Imai H, Haakenson JK, Brucklacher RM, Fox TE, Shanmugavelandy SS, Unrath KA, Pedersen MM, Dai P, Freeman WM, Bronson SK, Gardner TW, Kester M. Nanoliposomal minocycline for ocular drug delivery. Nanomedicine : Nanotechnology, Biology, and Medicine. 9: 130-40. PMID 22465498 DOI: 10.1016/J.Nano.2012.03.004  0.562
2013 Brown TJ, Garcia AM, Kissinger LN, Shanmugavel SS, Wang X, Cabot MC, Kester M, Claxton DF, Barth BM. Therapeutic Combination of Nanoliposomal Safingol and Nanoliposomal Ceramide for Acute Myeloid Leukemia Journal of Leukemia. 1: 1-9. DOI: 10.4172/2329-6917.1000110  0.448
2013 Morad SAF, Levin JC, Abdelmageed N, Kester M, Shanmugavdlandy SS, Paulson RF, Rosenberg DW, Madigan JP, Cabot MC. Abstract 2027: Tamoxifen amplifies antitumor impact of nanoformulated ceramide- pan efficacy in a myriad of tumor cell types. Cancer Research. 73: 2027-2027. DOI: 10.1158/1538-7445.Am2013-2027  0.506
2012 Morad SA, Levin JC, Shanmugavelandy SS, Kester M, Fabrias G, Bedia C, Cabot MC. Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer. Molecular Cancer Therapeutics. 11: 2352-61. PMID 22962326 DOI: 10.1158/1535-7163.Mct-12-0594  0.439
2012 Fox TE, Young MM, Pedersen MM, Han X, Gardner TW, Kester M. Diabetes diminishes phosphatidic acid in the retina: a putative mediator for reduced mTOR signaling and increased neuronal cell death. Investigative Ophthalmology & Visual Science. 53: 7257-67. PMID 22952117 DOI: 10.1167/Iovs.11-7626  0.577
2012 Watters RJ, Kester M, Tran MA, Loughran TP, Liu X. Development and use of ceramide nanoliposomes in cancer. Methods in Enzymology. 508: 89-108. PMID 22449922 DOI: 10.1016/B978-0-12-391860-4.00005-7  0.434
2012 Young MM, Takahashi Y, Khan O, Park S, Hori T, Yun J, Sharma AK, Amin S, Hu CD, Zhang J, Kester M, Wang HG. Autophagosomal membrane serves as platform for intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis. The Journal of Biological Chemistry. 287: 12455-68. PMID 22362782 DOI: 10.1074/Jbc.M111.309104  0.344
2012 Barth BM, Gustafson SJ, Hankins JL, Kaiser JM, Haakenson JK, Kester M, Kuhn TB. Ceramide kinase regulates TNFα-stimulated NADPH oxidase activity and eicosanoid biosynthesis in neuroblastoma cells. Cellular Signalling. 24: 1126-33. PMID 22230689 DOI: 10.1016/J.Cellsig.2011.12.020  0.793
2012 Avella DM, Li G, Schell TD, Liu D, Zhang SS, Lou X, Berg A, Kimchi ET, Tagaram HR, Yang Q, Shereef S, Garcia LS, Kester M, Isom HC, Rountree CB, et al. Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology (Baltimore, Md.). 55: 141-52. PMID 21898502 DOI: 10.1002/Hep.24652  0.301
2012 LeBlanc F, Liu X, Fox T, Shah M, Rogers A, Ryland L, Kester M, Yun J, Loughran TP. Targeting Sphingosine Kinase 1 in NK-LGL Leukemia Blood. 120: 1313-1313. DOI: 10.1182/Blood.V120.21.1313.1313  0.804
2011 Hankins JL, Fox TE, Barth BM, Unrath KA, Kester M. Exogenous ceramide-1-phosphate reduces lipopolysaccharide (LPS)-mediated cytokine expression. The Journal of Biological Chemistry. 286: 44357-66. PMID 22065582 DOI: 10.1074/Jbc.M111.264010  0.779
2011 Heakal Y, Kester M, Savage S. Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma. The Annals of Pharmacotherapy. 45: 1399-405. PMID 22028422 DOI: 10.1345/Aph.1Q363  0.764
2011 Jiang Y, DiVittore NA, Kaiser JM, Shanmugavelandy SS, Fritz JL, Heakal Y, Tagaram HR, Cheng H, Cabot MC, Staveley-O'Carroll KF, Tran MA, Fox TE, Barth BM, Kester M. Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer. Cancer Biology & Therapy. 12: 574-85. PMID 21795855 DOI: 10.4161/Cbt.12.7.15971  0.821
2011 Liao A, Broeg K, Fox T, Tan SF, Watters R, Shah MV, Zhang LQ, Li Y, Ryland L, Yang J, Aliaga C, Dewey A, Rogers A, Loughran K, Hirsch L, ... ... Kester M, et al. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. Blood. 118: 2793-800. PMID 21768294 DOI: 10.1182/Blood-2011-01-331447  0.804
2011 Heakal Y, Woll MP, Fox T, Seaton K, Levenson R, Kester M. Neurotensin receptor-1 inducible palmitoylation is required for efficient receptor-mediated mitogenic-signaling within structured membrane microdomains. Cancer Biology & Therapy. 12: 427-35. PMID 21725197 DOI: 10.4161/Cbt.12.5.15984  0.81
2011 Barth BM, Cabot MC, Kester M. Ceramide-based therapeutics for the treatment of cancer. Anti-Cancer Agents in Medicinal Chemistry. 11: 911-9. PMID 21707481 DOI: 10.2174/187152011797655177  0.421
2011 Barth BM, I AltinoÄŸlu E, Shanmugavelandy SS, Kaiser JM, Crespo-Gonzalez D, DiVittore NA, McGovern C, Goff TM, Keasey NR, Adair JH, Loughran TP, Claxton DF, Kester M. Targeted indocyanine-green-loaded calcium phosphosilicate nanoparticles for in vivo photodynamic therapy of leukemia. Acs Nano. 5: 5325-37. PMID 21675727 DOI: 10.1021/Nn2005766  0.384
2011 O'Neill SM, Yun JK, Fox TE, Kester M. Transcriptional regulation of the human neutral ceramidase gene. Archives of Biochemistry and Biophysics. 511: 21-30. PMID 21531200 DOI: 10.1016/J.Abb.2011.04.012  0.549
2011 O'Neill SM, Houck KL, Yun JK, Fox TE, Kester M. AP-1 binding transcriptionally regulates human neutral ceramidase. Archives of Biochemistry and Biophysics. 511: 31-9. PMID 21530485 DOI: 10.1016/J.Abb.2011.04.009  0.79
2011 Ryland LK, Fox TE, Liu X, Loughran TP, Kester M. Dysregulation of sphingolipid metabolism in cancer. Cancer Biology & Therapy. 11: 138-49. PMID 21209555 DOI: 10.4161/Cbt.11.2.14624  0.775
2011 Fox TE, Young MM, Pedersen MM, Giambuzzi-Tussey S, Kester M, Gardner TW. Insulin signaling in retinal neurons is regulated within cholesterol-enriched membrane microdomains. American Journal of Physiology. Endocrinology and Metabolism. 300: E600-9. PMID 21205932 DOI: 10.1152/Ajpendo.00641.2010  0.586
2011 Takahashi Y, Meyerkord CL, Hori T, Runkle K, Fox TE, Kester M, Loughran TP, Wang HG. Bif-1 regulates Atg9 trafficking by mediating the fission of Golgi membranes during autophagy. Autophagy. 7: 61-73. PMID 21068542 DOI: 10.4161/Auto.7.1.14015  0.585
2011 Fox TE, Bewley MC, Unrath KA, Pedersen MM, Anderson RE, Jung DY, Jefferson LS, Kim JK, Bronson SK, Flanagan JM, Kester M. Circulating sphingolipid biomarkers in models of type 1 diabetes. Journal of Lipid Research. 52: 509-17. PMID 21068007 DOI: 10.1194/Jlr.M010595  0.539
2011 Cabot MC, Karimi R, Kester M, Shanmugavelandy SS, Rosenberg DW, Madigan JP. Effect of tamoxifen on ceramide cytotoxicity in colon cancer cells. Journal of Clinical Oncology. 29: e14112-e14112. DOI: 10.1200/Jco.2011.29.15_Suppl.E14112  0.364
2010 Barth BM, Gustafson SJ, Young MM, Fox TE, Shanmugavelandy SS, Kaiser JM, Cabot MC, Kester M, Kuhn TB. Inhibition of NADPH oxidase by glucosylceramide confers chemoresistance. Cancer Biology & Therapy. 10: 1126-36. PMID 20935456 DOI: 10.4161/Cbt.10.11.13438  0.63
2010 Fox TE, Kester M. Therapeutic strategies for diabetes and complications: a role for sphingolipids? Advances in Experimental Medicine and Biology. 688: 206-16. PMID 20919656 DOI: 10.1007/978-1-4419-6741-1_14  0.541
2010 Adair JH, Parette MP, Altinoğlu EI, Kester M. Nanoparticulate alternatives for drug delivery. Acs Nano. 4: 4967-70. PMID 20873786 DOI: 10.1021/Nn102324E  0.342
2010 Liu X, Ryland L, Yang J, Liao A, Aliaga C, Watts R, Tan SF, Kaiser J, Shanmugavelandy SS, Rogers A, Loughran K, Petersen B, Yuen J, Meng F, Baab KT, ... ... Kester M, et al. Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. Blood. 116: 4192-201. PMID 20671121 DOI: 10.1182/Blood-2010-02-271080  0.803
2010 Winter JN, Fox TE, Kester M, Jefferson LS, Kimball SR. Phosphatidic acid mediates activation of mTORC1 through the ERK signaling pathway. American Journal of Physiology. Cell Physiology. 299: C335-44. PMID 20427710 DOI: 10.1152/Ajpcell.00039.2010  0.608
2010 Chapman JV, Gouazé-Andersson V, Messner MC, Flowers M, Karimi R, Kester M, Barth BM, Liu X, Liu YY, Giuliano AE, Cabot MC. Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches. Biochemical Pharmacology. 80: 308-15. PMID 20385104 DOI: 10.1016/J.Bcp.2010.04.001  0.332
2010 Ganapathi SB, Fox TE, Kester M, Elmslie KS. Ceramide modulates HERG potassium channel gating by translocation into lipid rafts. American Journal of Physiology. Cell Physiology. 299: C74-86. PMID 20375276 DOI: 10.1152/Ajpcell.00462.2009  0.787
2010 Barth BM, Sharma R, AltinoÄŸlu EI, Morgan TT, Shanmugavelandy SS, Kaiser JM, McGovern C, Matters GL, Smith JP, Kester M, Adair JH. Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo. Acs Nano. 4: 1279-87. PMID 20180585 DOI: 10.1021/Nn901297Q  0.333
2010 Wijesinghe DS, Allegood JC, Gentile LB, Fox TE, Kester M, Chalfant CE. Use of high performance liquid chromatography-electrospray ionization-tandem mass spectrometry for the analysis of ceramide-1-phosphate levels. Journal of Lipid Research. 51: 641-51. PMID 19654423 DOI: 10.1194/Jlr.D000430  0.56
2010 Fino KK, Matters GL, McGovern CO, Kester M, Smith JP. Abstract 4132: Down Regulation of the CCK-B/C Receptor Inhibits Growth of Pancreatic Cancer Cancer Research. 70: 4132-4132. DOI: 10.1158/1538-7445.Am10-4132  0.772
2009 Kline CL, Shanmugavelandy SS, Kester M, Irby RB. Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU. Cancer Biology & Therapy. 8: 1831-7. PMID 19729995 DOI: 10.4161/Cbt.8.19.9592  0.39
2009 Matters GL, Harms JF, McGovern CO, Jayakumar C, Crepin K, Smith ZP, Nelson MC, Stock H, Fenn CW, Kaiser J, Kester M, Smith JP. Growth of human pancreatic cancer is inhibited by down-regulation of gastrin gene expression. Pancreas. 38: e151-61. PMID 19465883 DOI: 10.1097/Mpa.0B013E3181A66Fdc  0.313
2009 Heakal Y, Kester M. Nanoliposomal short-chain ceramide inhibits agonist-dependent translocation of neurotensin receptor 1 to structured membrane microdomains in breast cancer cells. Molecular Cancer Research : McR. 7: 724-34. PMID 19435815 DOI: 10.1158/1541-7786.Mcr-08-0322  0.795
2009 Ganapathi SB, Kester M, Elmslie KS. State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy. American Journal of Physiology. Cell Physiology. 296: C701-10. PMID 19244476 DOI: 10.1152/Ajpcell.00633.2008  0.785
2009 Salli U, Fox TE, Carkaci-Salli N, Sharma A, Robertson GP, Kester M, Vrana KE. Propagation of undifferentiated human embryonic stem cells with nano-liposomal ceramide. Stem Cells and Development. 18: 55-65. PMID 18393629 DOI: 10.1089/Scd.2007.0271  0.609
2008 O'Neill SM, Olympia DK, Fox TE, Brown JT, Stover TC, Houck KL, Wilson R, Waybill P, Kozak M, Levison SW, Weber N, Karavodin LM, Kester M. C(6)-Ceramide-Coated Catheters Promote Re-Endothelialization of Stretch-Injured Arteries. Vascular Disease Prevention. 5: 200-210. PMID 19946459 DOI: 10.2174/156727008785133809  0.774
2008 Kester M, Heakal Y, Fox T, Sharma A, Robertson GP, Morgan TT, AltinoÄŸlu EI, Tabaković A, Parette MR, Rouse SM, Ruiz-Velasco V, Adair JH. Calcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells. Nano Letters. 8: 4116-21. PMID 19367878 DOI: 10.1021/Nl802098G  0.78
2008 Morgan TT, Muddana HS, Altinoglu EI, Rouse SM, Tabaković A, Tabouillot T, Russin TJ, Shanmugavelandy SS, Butler PJ, Eklund PC, Yun JK, Kester M, Adair JH. Encapsulation of organic molecules in calcium phosphate nanocomposite particles for intracellular imaging and drug delivery. Nano Letters. 8: 4108-15. PMID 19367837 DOI: 10.1021/Nl8019888  0.327
2008 Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, Smith NB, Robertson GP. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Research. 68: 7638-49. PMID 18794153 DOI: 10.1158/0008-5472.Can-07-6614  0.344
2008 Pearlman E, Johnson A, Adhikary G, Sun Y, Chinnery HR, Fox T, Kester M, McMenamin PG. Toll-like receptors at the ocular surface. The Ocular Surface. 6: 108-16. PMID 18781257 DOI: 10.1016/S1542-0124(12)70279-3  0.558
2008 Houck KL, Fox TE, Sandirasegarane L, Kester M. Ether-linked diglycerides inhibit vascular smooth muscle cell growth via decreased MAPK and PI3K/Akt signaling. American Journal of Physiology. Heart and Circulatory Physiology. 295: H1657-68. PMID 18723771 DOI: 10.1152/Ajpheart.00141.2008  0.808
2008 Tran MA, Smith CD, Kester M, Robertson GP. Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3571-81. PMID 18519791 DOI: 10.1158/1078-0432.Ccr-07-4881  0.416
2008 Zolnik BS, Stern ST, Kaiser JM, Heakal Y, Clogston JD, Kester M, McNeil SE. Rapid distribution of liposomal short-chain ceramide in vitro and in vivo. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 1709-15. PMID 18490436 DOI: 10.1124/Dmd.107.019679  0.79
2008 Sun Y, Fox T, Adhikary G, Kester M, Pearlman E. Inhibition of corneal inflammation by liposomal delivery of short-chain, C-6 ceramide. Journal of Leukocyte Biology. 83: 1512-21. PMID 18372342 DOI: 10.1189/Jlb.0108076  0.631
2008 Stover TC, Kim YS, Lowe TL, Kester M. Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug. Biomaterials. 29: 359-69. PMID 17964645 DOI: 10.1016/j.biomaterials.2007.09.037  0.805
2008 Liu X, Ryland L, Yang J, Aliaga C, Kaiser J, Zhang R, Thomas K, Jarbadan RN, Hughes J, Kester M, Loughran TP. Systemic Delivery of Nanoliposomal Ceramide Displays Anti-Leukemic Activity in a Rat Model of Large Granular Lymphocytic Leukemia Blood. 112: 3999-3999. DOI: 10.1182/Blood.V112.11.3999.3999  0.804
2007 Fox TE, Houck KL, O'Neill SM, Nagarajan M, Stover TC, Pomianowski PT, Unal O, Yun JK, Naides SJ, Kester M. Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains. The Journal of Biological Chemistry. 282: 12450-7. PMID 17308302 DOI: 10.1074/Jbc.M700082200  0.795
2007 Jiang Y, Kaiser J, Heakal Y, Cheng H, Loughran T, Kester M. Growth inhibitory effect of ceramide-incorporated nanoliposomes in human pancreatic cancer cells Journal of Clinical Oncology. 25: 14105-14105. DOI: 10.1200/Jco.2007.25.18_Suppl.14105  0.825
2006 Fox TE, Han X, Kelly S, Merrill AH, Martin RE, Anderson RE, Gardner TW, Kester M. Diabetes alters sphingolipid metabolism in the retina: a potential mechanism of cell death in diabetic retinopathy. Diabetes. 55: 3573-80. PMID 17130506 DOI: 10.2337/Db06-0539  0.563
2006 Fox TE, Finnegan CM, Blumenthal R, Kester M. The clinical potential of sphingolipid-based therapeutics. Cellular and Molecular Life Sciences : Cmls. 63: 1017-23. PMID 16568241 DOI: 10.1007/S00018-005-5543-Z  0.31
2005 Stover TC, Sharma A, Robertson GP, Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3465-74. PMID 15867249 DOI: 10.1158/1078-0432.Ccr-04-1770  0.807
2004 Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L, Robertson GP. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Research. 64: 7002-10. PMID 15466193 DOI: 10.1158/0008-5472.Can-04-1399  0.409
2003 Stover T, Kester M. Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. The Journal of Pharmacology and Experimental Therapeutics. 307: 468-75. PMID 12975495 DOI: 10.1124/Jpet.103.054056  0.817
2003 Kester M, Kolesnick R. Sphingolipids as therapeutics. Pharmacological Research. 47: 365-71. PMID 12676510 DOI: 10.1016/S1043-6618(03)00048-3  0.317
2002 Yun JK, Kester M. Regulatory role of sphingomyelin metabolites in hypoxia-induced vascular smooth muscle cell proliferation. Archives of Biochemistry and Biophysics. 408: 78-86. PMID 12485605 DOI: 10.1016/S0003-9861(02)00526-X  0.414
2002 Bourbon NA, Sandirasegarane L, Kester M. Ceramide-induced inhibition of Akt is mediated through protein kinase Czeta: implications for growth arrest. The Journal of Biological Chemistry. 277: 3286-92. PMID 11723139 DOI: 10.1074/Jbc.M110541200  0.813
2001 Kester M, Waybill P, Kozak M. New strategies to prevent restenosis. American Journal of Cardiovascular Drugs. 1: 77-83. PMID 14728037 DOI: 10.2165/00129784-200101020-00001  0.313
2001 Edwards L, Fishman D, Horowitz P, Bourbon N, Kester M, Ernsberger P. The I1-imidazoline receptor in PC12 pheochromocytoma cells activates protein kinases C, extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK). Journal of Neurochemistry. 79: 931-40. PMID 11739604 DOI: 10.1046/J.1471-4159.2001.00632.X  0.805
2001 Bourbon NA, Yun J, Berkey D, Wang Y, Kester M. Inhibitory actions of ceramide upon PKC-epsilon/ERK interactions. American Journal of Physiology. Cell Physiology. 280: C1403-11. PMID 11350735 DOI: 10.1152/Ajpcell.2001.280.6.C1403  0.808
2001 Sandirasegarane L, Kester M. Enhanced Stimulation of Akt-3/Protein Kinase B-γ in Human Aortic Smooth Muscle Cells Biochemical and Biophysical Research Communications. 283: 158-163. PMID 11322783 DOI: 10.1006/Bbrc.2001.4739  0.381
2000 Bourbon NA, Yun J, Kester M. Ceramide directly activates protein kinase C zeta to regulate a stress-activated protein kinase signaling complex. The Journal of Biological Chemistry. 275: 35617-23. PMID 10962008 DOI: 10.1074/Jbc.M007346200  0.806
2000 Sandirasegarane L, Charles R, Bourbon N, Kester M. NO regulates PDGF-induced activation of PKB but not ERK in A7r5 cells: implications for vascular growth arrest. American Journal of Physiology. Cell Physiology. 279: C225-35. PMID 10898734 DOI: 10.1152/Ajpcell.2000.279.1.C225  0.803
1999 Alpert SE, Walenga RW, Mandal A, Bourbon N, Kester M. 15-HETE-substituted diglycerides selectively regulate PKC isotypes in human tracheal epithelial cells. The American Journal of Physiology. 277: L457-64. PMID 10484452 DOI: 10.1152/Ajplung.1999.277.3.L457  0.811
1999 Separovic D, Pink JJ, Oleinick NA, Kester M, Boothman DA, McLoughlin M, Peña LA, Haimovitz-Friedman A. Niemann-Pick human lymphoblasts are resistant to phthalocyanine 4-photodynamic therapy-induced apoptosis. Biochemical and Biophysical Research Communications. 258: 506-512. PMID 10329416 DOI: 10.1006/Bbrc.1999.0670  0.376
Show low-probability matches.